v3.26.3
Notes to the interim condensed consolidated statement of income (loss) - Share of net profit - Equity method (Details) - EUR (€)
€ in Thousands
 6 Months Ended 12 Months Ended
Feb. 24, 2026
Jan. 14, 2026
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Investments accounted for using the equity method          
General and administrative expenses     € (22,247) € (14,713)  
Net operating loss     (70,388) (62,940)  
Financial income     74,910 2,427  
Financial expenses     (74,004) (115,651)  
Net financial income     907 (113,224)  
Net loss for the period     (69,467) (175,882)  
Exchange difference on translation of foreign operations     (59) (77)  
Items that will be reclassified subsequently to profit or loss     (175) (260)  
Total comprehensive loss     € (69,570) € (176,049)  
Hepalys Pharma, Inc          
Investments accounted for using the equity method          
Group's share in % 13.68% 13.92% 13.68% 15.00% 14.64%
Share of net loss     € (227) € (334)  
Elimination of downstream sales     54 113  
Share of net profit (loss) - Equity method     (172) (220)  
Hepalys Pharma, Inc          
Investments accounted for using the equity method          
General and administrative expenses     (1,624) (2,155)  
Net operating loss     (1,624) (2,155)  
Financial income     32 2  
Financial expenses     (49) (5)  
Net financial income     (17) (3)  
Net loss for the period     (1,642) (2,158) € (3,816)
Exchange difference on translation of foreign operations     (70) (573)  
Items that will be reclassified subsequently to profit or loss     (70) (573)  
Total comprehensive loss     € (1,712) € (2,732)